文献速递慢性肾脏病血液净化与透析

慢性肾脏病合并2型糖尿病患者治疗需求高度未满足:来自美国理赔数据库的真实世界证据

High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

基于美国2007年1月1日至2019年3月31日理赔数据的回顾性研究,纳入新发CKD队列63127例和现患CKD队列326763例2型糖尿病患者,评估降压和降糖药物起始与停药情况。推荐治疗起始率低(ACEi/ARB 17.8%、SGLT2i 2.5%)且停药率高(ACEi/ARB 56.0%、SGLT2i 65.0%),提示指南依从性欠佳。

要点

  • 新发CKD队列中ACEi/ARB起始率17.8%、停药率56.0%,SGLT2i起始率2.5%、停药率65.0%。
  • 临床结局发生率从全因死亡35.07/1000人年至ESKD 104.19/1000人年,全因住院283.14/1000人年。
  • 合并症患者临床和经济结局更高,高危CKD亚组可能从进一步治疗选择中获益。

核心结论

  • 结果凸显CKD合并T2D患者治疗需求高度未满足,尤其是多合并CVD、高危CKD(低eGFR或高UACR)或快速进展CKD亚组。
  • 推荐治疗起始率低、停药率高,提示为延缓CKD进展的指南依从性欠佳。
  • 这些高危患者可能从进一步治疗选择中获益,以改善发病率和死亡率并减轻经济负担。

研究设计与样本

  • 回顾性研究,使用美国2007年1月1日至2019年3月31日的行政理赔数据。
  • 新发CKD队列63127例,现患CKD队列326763例,均为合并T2D的CKD患者。
  • 评估降压药(ACEi/ARB、甾体类盐皮质激素受体拮抗剂)和降糖药(SGLT2i、DPP4i、GLP-1 RA、胰岛素、磺脲类)的联合使用、新起始和停药比例,以及每1000人年临床结局发生率和平均总医疗费用。

主要发现

  • 新起始率与停药率分别为:ACEi/ARB 17.8%与56.0%,sMRA 1.3%与66.0%,SGLT2i 2.5%与65.0%,DPP4i 3.7%与66.8%,GLP-1 RA 2.31%与69.0%,胰岛素4%与75.7%,磺脲类5.5%与56.9%。
  • 亚组结果类似。
  • 临床结局发生率从全因死亡35.07/1000人年至ESKD 104.19/1000人年,住院率从肾脏住院36.61/1000人年至全因住院283.14/1000人年。
  • 合并症患者临床和经济结局更高。

关键数值与推荐

  • 治疗指南推荐肾素-血管紧张素阻断以及二甲双胍和SGLT2i降糖治疗作为一线治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease (CKD), a serious complication of type 2 diabetes (T2D) increases the comorbid risk of cardiovascular disease (CVD) and end-stage kidney disease(ESKD). Treatment guidelines recommend renin-angiotensin blockade and antihyperglycemic treatment with metformin and sodium-glucose cotransporter 2 inhibitors (SGLT2is) as first-line treatment. We evaluated treatment initiation and discontinuation overall and in subgroups of T2D patients with incident CKD (incident cohort) and rates of clinical and economic outcomes in patients with T2D and any CKD (prevalent cohort). METHODS: In this retrospective study of administrative claims in the USA between 1 January 2007 and 31 March 2019, we evaluated the proportion of patients with concomitant, newly initiated and discontinued use of antihypertensive [angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blockers (ARBs), steroidal mineralocorticoid receptor antagonists (sMRAs)] and antidiabetic [SGLT2is, dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), insulin and sulfonylureas] medications, rates of clinical outcomes per 1000 person-years and mean total healthcare costs. RESULTS: We identified 63 127 and 326 763 patients in the incident and prevalent CKD cohorts, respectively. Low initiation and high discontinuation rates were observed with 17.8% and 56.0% for ACEi/ARBs, 1.3% and 66.0% for sMRAs, 2.5% and 65.0% for SGLT2is, 3.7% and 66.8% for DPP4is, 2.31% and 69.0% for GLP-1 RAs, 4% and 75.7% for insulin and 5.5% and 56.9% for sulfonylureas. Similar results were seen by subgroups. Rates of clinical outcomes ranged from 35.07 per 1000 person-years for all-cause mortality to 104.19 for ESKD, with rates of hospitalization ranging from 36.61 for kidney hospitalizations to 283.14 for all-cause hospitalizations. Among patients with comorbidities, higher clinical and economic outcomes were found. CONCLUSION: Our results highlight high unmet needs of CKD and T2D, particularly subgroups of patients with multimorbid CVD, high-risk CKD (low estimated glomerular filtration rate or high urinary albumin:creatinine ratio) or rapidly progressing CKD. Low initiation and high discontinuation of recommended treatments suggest that adherence to guidelines for halting CKD progression is suboptimal. These high-risk patients may benefit from further treatment options to improve morbidity and mortality and reduce the economic burden.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Fried L, Schmedt N, Folkerts K, et al. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database. Nephrol Dial Transplant. 2023. PMID: 35389468. doi:10.1093/ndt/gfac140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。